Our current investments include

- **Preventive treatment including long-acting formulations** for people with latent TB, such as children and people living with HIV: $60 m
- **Better treatments** halving treatment time for all forms of resistant tuberculosis; improved TB and MDR-TB treatment for children; and helping patients succeed in TB treatment through digital adherence technologies: $115 m
- **Strengthening TB diagnosis** detecting TB in children early; bringing high-tech tests for fast and accurate diagnosis of drug-resistant TB; integrating TB screening with other health services such as HIV, nutrition, maternal and child health: $65 m
- **Our TB portfolio keeps growing** with investments on track to hit US$ 300 million in 2020:

  - 2016: $127 m
  - 2018: $215 m
  - 2020: $300 m

Unitaid's current main funders are France, the United Kingdom, Brazil, Norway, Chile, the Republic of Korea, Spain, and the Bill & Melinda Gates Foundation.

Unitaid is a hosted partnership of the World Health Organization.